HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Samantha DiGrande


Cost of Care: Outlining the Risks That Go Along With the Benefit of CAR T-Cell Therapy

July 16, 2019

Cytokine release syndrome represents a major concern, and source of costs, associated with the life-saving gene therapy.

Outlining the Risks That Go Along With the Benefit of CAR T-Cell Therapy

June 05, 2019

Though chimeric antigen receptor (CAR) T-cell therapy has been largely touted as one of the most important advances in cancer care in recent years, the therapy comes with the risk of severe toxicities as well as increased financial burden due to the high cost of the drugs.

NCCN Report on CAR T-Cell Therapy, Recommendations for Future Use

September 14, 2018

A recent report from the National Comprehensive Cancer Network (NCCN) investigated the current state of chimeric antigen receptor (CAR) T-cell therapy and future strategies to consider as the novel immunotherapy evolves and is used in the treatment of more patients.

MD Anderson, PALISI Jointly Develop Pediatric Guidelines for CAR T-Cell Therapy

August 09, 2018

Researchers from the University of Texas MD Anderson Cancer Center, along with the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI), recently published guidelines in Nature Reviews Clinical Oncology for the management of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia.

FDA Accepts First Allogeneic CAR T-Cell Therapy Trial

August 04, 2018

Celyad, a biopharmaceutical company that focuses on the development of chimeric antigen receptor (CAR) T-cell therapies, recently announced that the FDA has accepted its Investigational New Drug (IND) application for CYAD-101, the first non–gene-edited allogeneic clinical program.

AbbVie and Calibr to Collaborate on CAR T-Cell Development

June 29, 2018

Drug manufacturer AbbVie, and a nonprofit drug discovery division of Scripps Research, Calibr, announced earlier this week that they are partnering to develop chimeric antigen receptor (CAR-T) cell therapies primarily aimed at treating cancer, particularly, solid tumors.

Nivolumab Gains First Indication in China for NSCLC

June 20, 2018

Last week, Bristol-Myers Squibb announced that the China National Drug Administration approved the country’s first immuno-oncology and first PD-1 therapy, nivolumab (Opdivo), for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).

RA Drug May Reduce Toxicity Caused By CAR T Treatment

June 15, 2018

Last year, the FDA expanded the indications of rheumatoid arthritis (RA) drug tocilizumab (Actemra) to include the treatment of cytokine release syndrome (CRS) caused by CAR T-cell therapy. Recently, 2 studies have identified another rheumatoid arthritis drug that could be more effective in the treatment of CRS.